Benny Sorensen
President, CEO & DirectorDr. Benny Sorensen, M.D., Ph.D., is Director at Hemab ApS since 2023 and serves as its Chief Executive Officer. Dr. Sorensen has been the Chief Executive Officer and President at Hemab Therapeutics Holdings, Inc. since July 2021 and its Director since November 2021. He served as Member of Advisory Board at Codiak BioSciences, Inc. since July 6, 2021 until April 2023 and served as consultant role for Codiak BioSciences, Inc. until April 2023. He served as Senior Vice President of Strategic Projects at Codiak BioSciences, Inc. since May 2021 until July 6, 2021 and served as Senior Vice President and Head of Clinical Development until May 2021. He served as Senior Vice President of Clinical Development at Codiak BioSciences, Inc., since July 2019 and joined in October 2016. He served as Senior Vice President of Codiak BioSciences, Inc. since July 30, 2019. Dr. Sorensen had been the Head of Clinical Development at Codiak Biosciences, Inc. since October 2016 and served as Vice President since October 2016 until July 30, 2019. Dr. Sorensen leads clinical drug-development and medical strategy. Dr. Sorensen served as a Senior Director of Clinical Research at Alnylam Pharmaceuticals, Inc. since November 2013, leading preclinical as well as clinical, regulatory, medical affairs and commercial development strategies for hematology products. Dr. Sorensen has joined Alnylam and has experience in clinical and academic hemophilia and hemostasis research and management. Before Alnylam, Dr. Sorensen served as a Global Medical Director at Baxter Healthcare Corporation, where he was responsible for developing clinical, regulatory, commercial and business development strategies for hemophilia products and services and advanced phase three pivotal development of Adynovate® and Vonvendi®. Prior to Baxter, he served as the Director of the Haemostasis Research Unit and was Honorary Lecturer at Guy's and St. Thomas' Hospital & King's College London School of Medicine, where he led the advancement of several clinical trials across Phases I, II and III. Dr. Sorensen has published extensively on the topics of hemophilia and hemostasis management. Dr. Sorensen has served on the board of directors of Hemab ApS since November 2020. Dr. Sorensen has published extensively in hematology translational and clinical research. He holds an M.D. and Ph.D. from Aarhus University, Denmark.
Positions
- Company NameHemab Therapeutics Holdings, Inc.Stock CodeCOAGPositionPresident, CEO & DirectorColleagues
- JMJohn Michael MaraganoreIndependent Chairman
- MNMads Nikolaj Behrndt-EriksenCFO & GM
- CECatherine Eilleen MadiganChief Medical Officer
- ASAnanthram Sreenivasa MurthyChief Operating Officer
- KWKaren WeisbachChief People & Culture Officer
- LCLinda Cathavina BainIndependent Director
- AKAkshay Krishnadas VaishnawIndependent Director
- KWKeli WalbertDirector
